

Removal of Temporary Benefit from the Alberta Human Services Drug Benefit Supplement (HSDBS)

Due to the shortage of Nestle Materna Tablet (NPN 80082297), **Prenatal 100% Complete Multivitamin Tablet (NPN 80075639)**, manufactured by Jamieson Laboratories Ltd., was added as a temporary benefit for the *Alberta Human Services Drug Benefit Supplement (HSDBS)*.

Alberta Blue Cross has confirmed that the shortage for Nestle Materna Tablet (NPN 80082297) has been resolved.

As a result, **Prenatal 100% Complete Multivitamin Tablet (NPN 80075639)** will no longer be considered a temporary benefit for the *HSDBS* after **November 1, 2024**. The above grouping was removed from the Critical Supply Product List on **October 1, 2024**.

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has confirmed that the shortage for Apo-Cabergoline 0.5 mg Tablet (DIN 02455897) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the Least Cost Alternative (LCA) Price Policy will be reapplied to the following grouping effective **November 15, 2024**. The following grouping was removed from the Critical Supply Product List on **October 16, 2024**:

CABERGOLINE

0.5 MG TABLET

00002455897	APO-CABERGOLINE	APX	\$12.3941
00002242471	DOSTINEX	PAL	\$ 16.7022

Alberta Blue Cross has confirmed that the shortages for Apo-Darifenacin 7.5 mg Extended-Release Tablet (DIN 02452510) and Jamp Darifenacin 7.5 mg Extended-Release Tablet (DIN 02491869) have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **November 15, 2024**. The following grouping was removed from the Critical Supply Product List on **October 16, 2024**:

DARIFENACIN HYDROBROMIDE

7.5 MG EXTENDED-RELEASE TABLET

00002452510	APO-DARIFENACIN	APX	\$ 0.8058
00002491869	JAMP DARIFENACIN	JPC	\$ 0.8058
00002273217	ENABLEX	SLP	\$ 1.6400

continued next page

PHARMACY BENEFACT

continued from previous page

Alberta Blue Cross has confirmed that the shortage for the following products below has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **November 15, 2024**. The following grouping was removed from the Critical Supply Product List on **October 16, 2024**:

LATANOPROST

0.005% OPHTHALMIC SOLUTION

00002296527	APO-LATANOPROST	APX	\$ 3.6320
00002373041	GD-LATANOPROST	UJC	\$ 3.6320
00002453355	JAMP-LATANOPROST	JPC	\$ 3.6320
00002489570	LATANOPROST	TGT	\$ 3.6320
00002513285	M-LATANOPROST	MTR	\$ 3.6320
00002426935	MED-LATANOPROST	GMP	\$ 3.6320
00002367335	SANDOZ LATANOPROST	SDZ	\$ 3.6320
00002254786	TEVA-LATANOPROST	TEV	\$ 3.6320
00002231493	XALATAN	BGP	\$ 1.6400

Alberta Blue Cross has confirmed that the shortage for GLN-Atovaquone 150 mg/ml Oral Suspension (DIN 02528495) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **November 18, 2024**. The following grouping was removed from the Critical Supply Product List on **October 17, 2024**:

ATOVAQUONE

150 MG / ML ORAL SUSPENSION

00002528495	GLN-ATOVAQUONE	GLM	\$ 2.3785
00002217422	MEPRON	GSK	\$ 3.1634

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

